Cargando…

Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?

BACKGROUND: The advent of therapeutic strategies designed to modify the disease course in Parkinson’s disease has raised great expectations in the currently conducted clinical trials. However, we see ethical challenges in the cooperation of industry and clinical partners, specifically evident in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berg, D., Eggert, K., Haslinger, B., Kassubek, J., Mollenhauer, B., Reetz, K., Rogge, A., Schaeffer, E., Tönges, L., Zeuner, K. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Position Statement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650104/ https://www.ncbi.nlm.nih.gov/pubmed/33324933 http://dx.doi.org/10.1186/s42466-020-00076-y

Ejemplares similares

Position Statement from the German Biobank Alliance on the Cooperation Between Academic Biobanks and Industry Partners
por: Baber, Ronny, et al.
Publicado: (2019)

Can Treatment Adherence Be Improved by Using Rubin's Four Tendencies Framework to Understand a Patient's Response to Expectations
por: Kirk, Jeremy, et al.
Publicado: (2017)

Can Treatment Adherence Be Improved by Using Rubin's Four Tendencies Framework to Understand a Patient's Response to Expectations
por: Kirk, Jeremy, et al.
Publicado: (2017)

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*
por: Jee, Adelle S., et al.
Publicado: (2020)

Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
por: Mulberg, Andrew E., et al.
Publicado: (2019)

Epidemiology of rare diseases in Brazil: protocol of the Brazilian Rare Diseases Network (RARAS-BRDN)
por: Félix, Têmis Maria, et al.
Publicado: (2022)

Clinical management guidelines for Friedreich ataxia: best practice in rare diseases
por: Corben, Louise A., et al.
Publicado: (2022)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Expansion of India’s national child healthcare programme, Rashtriya Bal Swasthya Karyakram (RBSK), for rare disease management : a health policy perspective
por: Chaube, Pragya, et al.
Publicado: (2023)

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic
por: Brizola, E., et al.
Publicado: (2020)

Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
por: Rudebeck, Mattias, et al.
Publicado: (2021)

American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States
por: Mahmoudjafari, Zahra, et al.
Publicado: (2020)

ERNICA guidelines for the management of rectosigmoid Hirschsprung’s disease
por: Kyrklund, Kristiina, et al.
Publicado: (2020)

Data silos are undermining drug development and failing rare disease patients
por: Denton, Nathan, et al.
Publicado: (2021)

Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
por: Di Rocco, Maja, et al.
Publicado: (2020)

Sharing is caring: a call for a new era of rare disease research and development
por: Denton, Nathan, et al.
Publicado: (2022)

Compounded medication for patients with rare diseases
por: Dooms, Marc, et al.
Publicado: (2018)

French recommendations for the management of Behçet’s disease
por: Kone-Paut, Isabelle, et al.
Publicado: (2021)

Rare diseases in Tanzania: a National Call for Action to address policy and urgent needs of individuals with rare diseases
por: Kaywanga, Frida, et al.
Publicado: (2022)

Position paper: ability to drive in cerebrovascular diseases
por: Marx, Peter, et al.
Publicado: (2019)

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease
por: Fratz, Sohrab, et al.
Publicado: (2013)

From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research
por: Kaufmann, Petra, et al.
Publicado: (2018)

eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
por: Paglialonga, Alessia, et al.
Publicado: (2021)

Rare disease education in Europe and beyond: time to act
por: Tumiene, Birute, et al.
Publicado: (2022)

Pharmacists are initiators in palliative care for patients with rare diseases
por: Dooms, M.
Publicado: (2023)

Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit
por: Metsios, George S., et al.
Publicado: (2021)

European Reference networks for rare diseases: what is the conceptual framework?
por: Héon-Klin, Véronique
Publicado: (2017)

A patient advocating for transparent science in rare disease research
por: Yang, Richard Rui
Publicado: (2023)

Increasing African genomic data generation and sharing to resolve rare and undiagnosed diseases in Africa: a call-to-action by the H3Africa rare diseases working group
por: Lumaka, Aimé, et al.
Publicado: (2022)

Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins)
por: Mosbah, H., et al.
Publicado: (2022)

European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants
por: van de Laar, Ingrid M. B. H., et al.
Publicado: (2019)

Pharmaceutical pricing, cost containment and new treatments for rare diseases in children
por: Stella, Peter, et al.
Publicado: (2014)

Rare diseases in Chile: challenges and recommendations in universal health coverage context
por: Encina, Gonzalo, et al.
Publicado: (2019)

ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic
por: Mazer-Amirshahi, Maryann, et al.
Publicado: (2020)

European expert network on rare communicable diseases and other rare diseases linked to mobility and globalisation focused on health care provision (EURaDMoG): a feasibility study
por: Requena-Méndez, Ana, et al.
Publicado: (2020)

The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks
por: Evangelista, Teresinha, et al.
Publicado: (2016)

Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*
por: Dummer, Jack, et al.
Publicado: (2020)

Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
por: Adams, David, et al.
Publicado: (2021)

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases
por: Douglas, Conor M. W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_io70g57hbhejdfo1ug09nq4rka